Apricus Biosciences, Inc. Email Format

PharmaceuticalsCalifornia, United States11-50 Employees

Apricus Biosciences, Inc. is a San Diego–based biopharmaceutical company focused on developing medicines for urology and rheumatology. Its pipeline includes fispemifene, a selective estrogen receptor modulator being studied in a Phase 2b trial for symptomatic male secondary hypogonadism, along with plans for additional studies in other urological conditions. The company has also completed enrollment in a Phase 2a trial for RayVa™, aimed at treating Raynaud’s phenomenon, and is pursuing a second-generation, room-temperature formulation of its ED treatment Vitaros®, which is already approved in Europe and Canada and marketed in several European markets through multiple partners. 
Apricus operates within the pharmaceutical manufacturing and biopharma sector, collaborating with regional and international marketing partners to commercialize Vitaros® in various countries. Its headquarters are in San Diego, California, and the organization has a presence in the publicly traded arena on the Nasdaq Capital Market under the ticker APRI. The firm’s activities reflect a focus on therapeutics in two specialty areas, supported by ongoing clinical development and international distribution arrangements.

Get verified Apricus Biosciences, Inc. emails free

Company overview Employee directory